Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

507 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prevalence of comorbid autoimmune diseases and antibodies in newly diagnosed multiple sclerosis patients.
Jendretzky KF, Lezius LM, Thiele T, Konen FF, Huss A, Heitmann L, Güzeloglu YE, Schwenkenbecher P, Sühs KW, Skuljec J, Wattjes MP, Witte T, Kleinschnitz C, Pul R, Tumani H, Gingele S, Skripuletz T. Jendretzky KF, et al. Among authors: kleinschnitz c. Neurol Res Pract. 2024 Nov 12;6(1):55. doi: 10.1186/s42466-024-00351-2. Neurol Res Pract. 2024. PMID: 39533435 Free PMC article.
Real-world therapy management of patients with multiple sclerosis receiving cladribine tablets beyond year 4 - Results from a German cladribine cohort.
Kowarik MC, Ernst M, Woitschach L, Cepek L, Rau D, Kühnler B, Schlemilch-Paschen S, Grothe C, Schwab M, Jöstingmeyer P, Kleinschnitz C, Pul R. Kowarik MC, et al. Among authors: kleinschnitz c. Mult Scler Relat Disord. 2024 Aug;88:105704. doi: 10.1016/j.msard.2024.105704. Epub 2024 Jun 7. Mult Scler Relat Disord. 2024. PMID: 38878625 Free article.
Cognition in patients with myelin oligodendrocyte glycoprotein antibody-associated disease: a prospective, longitudinal, multicentre study of 113 patients (CogniMOG-Study).
Passoke S, Stern C, Häußler V, Kümpfel T, Havla J, Engels D, Jarius S, Wildemann B, Korporal-Kuhnke M, Senel M, Stellmann JP, Warnke C, Grothe M, Schülke R, Gingele S, Kretschmer JR, Klotz L, Walter A, Then Bergh F, Aktas O, Ringelstein M, Ayzenberg I, Schwake C, Kleiter I, Sperber PS, Rust R, Schindler P, Bellmann-Strobl J, Paul F, Kopp B, Trebst C, Hümmert MW; Neuromyelitis Optica Study Group (NEMOS). Passoke S, et al. J Neurol Neurosurg Psychiatry. 2024 Jul 30:jnnp-2024-333994. doi: 10.1136/jnnp-2024-333994. Online ahead of print. J Neurol Neurosurg Psychiatry. 2024. PMID: 39084862 Free article.
Apheresis therapies in MOGAD: a retrospective study of 117 therapeutic interventions in 571 attacks.
Schwake C, Ladopoulos T, Häußler V, Kleiter I, Ringelstein M, Aktas O, Kümpfel T, Engels D, Havla J, Hümmert MW, Kretschmer JR, Tkachenko D, Trebst C, Ayroza Galvão Ribeiro Gomes AB, Pröbstel AK, Korporal-Kuhnke M, Wildemann B, Jarius S, Pul R, Pompsch M, Krämer M, Then Bergh F, Gödel C, Schwarz P, Kowarik MC, Rommer PS, Vardakas I, Senel M, Winkelmann A, Retzlaff N, Weber MS, Husseini L, Walter A, Schindler P, Bellmann-Strobl J, Paul F, Gold R, Ayzenberg I; Neuromyelitis Optica Study Group (NEMOS). Schwake C, et al. J Neurol Neurosurg Psychiatry. 2024 Nov 4:jnnp-2024-334863. doi: 10.1136/jnnp-2024-334863. Online ahead of print. J Neurol Neurosurg Psychiatry. 2024. PMID: 39496464 Free article.
Correction to: Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) - revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: Attack therapy and long-term management.
Kümpfel T, Giglhuber K, Aktas O, Ayzenberg I, Bellmann-Strobl J, Häußler V, Havla J, Hellwig K, Hümmert MW, Jarius S, Kleiter I, Klotz L, Krumbholz M, Paul F, Ringelstein M, Ruprecht K, Senel M, Stellmann JP, Bergh FT, Trebst C, Tumani H, Warnke C, Wildemann B, Berthele A; Neuromyelitis Optica Study Group (NEMOS). Kümpfel T, et al. J Neurol. 2024 Jun;271(6):3702-3707. doi: 10.1007/s00415-024-12288-2. J Neurol. 2024. PMID: 38578500 Free PMC article. No abstract available.
Longitudinal optic neuritis-unrelated visual evoked potential changes in NMO spectrum disorders.
Ringelstein M, Harmel J, Zimmermann H, Brandt AU, Paul F, Haarmann A, Buttmann M, Hümmert MW, Trebst C, Schroeder C, Ayzenberg I, Kleiter I, Hellwig K, Havla J, Kümpfel T, Jarius S, Wildemann B, Rommer P, Weber MS, Pellkofer H, Röpke L, Geis C, Retzlaff N, Zettl U, Deppe M, Klotz L, Young K, Stellmann JP, Kaste M, Kermer P, Marouf W, Lauda F, Tumani H, Graf J, Klistorner A, Hartung HP, Aktas O, Albrecht P; Neuromyelitis Optica Study Group (NEMOS). Ringelstein M, et al. Neurology. 2020 Jan 28;94(4):e407-e418. doi: 10.1212/WNL.0000000000008684. Epub 2019 Dec 3. Neurology. 2020. PMID: 31796527
Treatment switches of disease-modifying therapies in people with multiple sclerosis: long-term experience from the German MS Registry.
Frahm N, Ellenberger D, Stahmann A, Fneish F, Lüftenegger D, Salmen HC, Schirduan K, Schaak TPA, Flachenecker P, Kleinschnitz C, Paul F, Krefting D, Zettl UK, Peters M, Warnke C. Frahm N, et al. Among authors: kleinschnitz c. Ther Adv Neurol Disord. 2024 Mar 29;17:17562864241239740. doi: 10.1177/17562864241239740. eCollection 2024. Ther Adv Neurol Disord. 2024. PMID: 38560408 Free PMC article.
Failure of natalizumab to prevent relapses in neuromyelitis optica.
Kleiter I, Hellwig K, Berthele A, Kümpfel T, Linker RA, Hartung HP, Paul F, Aktas O; Neuromyelitis Optica Study Group. Kleiter I, et al. Arch Neurol. 2012 Feb;69(2):239-45. doi: 10.1001/archneurol.2011.216. Arch Neurol. 2012. PMID: 22332191
Vitamin D, smoking, EBV, and long-term cognitive performance in MS: 11-year follow-up of BENEFIT.
Cortese M, Munger KL, Martínez-Lapiscina EH, Barro C, Edan G, Freedman MS, Hartung HP, Montalbán X, Foley FW, Penner IK, Hemmer B, Fox EJ, Schippling S, Wicklein EM, Kappos L, Kuhle J, Ascherio A; BENEFIT Study Group. Cortese M, et al. Neurology. 2020 May 5;94(18):e1950-e1960. doi: 10.1212/WNL.0000000000009371. Epub 2020 Apr 16. Neurology. 2020. PMID: 32300060 Free PMC article. Clinical Trial.
Efficacy of glatiramer acetate in neuromyelitis optica spectrum disorder: a multicenter retrospective study.
Ayzenberg I, Schöllhammer J, Hoepner R, Hellwig K, Ringelstein M, Aktas O, Kümpfel T, Krumbholz M, Trebst C, Paul F, Pache F, Obermann M, Zeltner L, Schwab M, Berthele A, Jarius S, Kleiter I; Neuromyelitis Optica Study Group. Ayzenberg I, et al. J Neurol. 2016 Mar;263(3):575-82. doi: 10.1007/s00415-015-7991-1. Epub 2016 Jan 25. J Neurol. 2016. PMID: 26810718
507 results